This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Lorand, L. Search for Related Content PubMed PubMed Citation Articles by Lorand, L. Related Collections Thrombolysis Coagulation and fibronolysis

(Arteriosclerosis, Thrombosis, and Vascular Biology. 2000;20:2.)
© 2000 American Heart Association, Inc.

Brief Review

Sol Sherry Lecture in Thrombosis

Research on Clot Stabilization Provides Clues for Improving Thrombolytic Therapies

Laszlo Lorand

From the Department of Cell and Molecular Biology and the Feinberg Cardiovascular Research Institute, Northwestern University Medical School, Chicago, Ill.

Correspondence to Laszlo Lorand, Department of Cell and Molecular Biology, Northwestern University Medical School, Searle 4-555, 303 E Chicago Avenue, Chicago, IL 60611-3008. E-mail l-lorand{at}nwu.edu

Key Words: Fibrin • Factor XIII • inhibitors • thrombolysis

	Introduction

Top Introduction The Urea-Soluble Clot The Urea-Insoluble Clot Activation and Regulation of... Determinants of the... What Lessons Can be... Therapeutic Possibilities References

 
This article is a summary of the Sol Sherry Lecture of the Council on Arteriosclerosis, Thrombosis, and Vascular Biology, which was presented at the 71st Scientific Sessions of the American Heart Association in November 1998.¹ It highlights the work from our laboratory, designed to dissect the intricate reactions and molecular control mechanisms that operate in the final stages of the coagulation cascade. This research brought forth the idea that, by selectively blocking the maturation and accretion of thrombi, we should be able to achieve a much safer and more efficient thrombolysis at lower dosages of clot dissolving agents than currently in use.

Fibrin is the fundamental building block of the clot matrix. Network formation occurs in an orderly sequence, well separated in time into distinct phases during the course of coagulation of normal plasma. After the reaction of thrombin with fibrinogen, a protofibrillar lattice is formed, with fibrin units lined up in a half-staggered array, reminiscent of laying bricks without mortar (Figure 1, top panel). Lateral bundling into filaments and fibers with concomitant entanglements and branching generates a 3D gel, the appearance of which is a measure of "clotting time." Then, under the influence of the activated fibrin stabilizing factor (factor XIIIa), covalent bonds are introduced into the structure that causes an irreversible, end-to-end fusion of the fibrin particles (Figure 1, middle panel). Finally, full maturation of the network is brought about by forming covalent bonds between the protofibrils and filaments (Figure 1, bottom panel). Clots displaying the features shown in the top panel of Figure 1 can be readily dissociated into monomeric fibrin in 5 mol/L urea^{2 3} and on removal of urea, the gel reforms. The equilibrium between the monomeric or low oligomeric forms of soluble fibrin and clotted fibrin can be described as:

View larger version (23K): [in this window] [in a new window]   Figure 1. Stages in the formation and maturation of fibrin clots. Clotting time is defined by the rate of assembly of the protein into structures as illustrated in the top panel. Such clots, obtained in mixtures of fibrinogen or Ca2+-chelated (citrate, ethylenediaminetetraacetic acid) plasma with thrombin, can be reversibly dissociated into fibrin monomers, proving that these clots—in contrast to the covalently linked polymers in the urea-insoluble structures shown in the middle and bottom panels—are made up of fibrin molecules held together only by weak secondary bonds.

View larger version (5K): [in this window] [in a new window]   Figure 8.

In contrast to this, the factor XIIIa-stabilized networks, shown in the middle and bottom panels of Figure 1, cannot be dispersed in urea. (As a historical aside, it is interesting to observe that the question of whether fibrin could be dispersed in urea or not has been investigated and debated in the literature for more than 100 years [see reference 4], with some researchers answering in the affirmative, others in the negative. In view of what we now know,^{2 3} both sides may have been right on this issue).

An appropriate therapeutic aim for helping individuals with thrombotic tendencies would be to block the factor XIIIa-mediated reactions in a well controlled and highly selective manner without interfering with the primary "clotting time." This would result in preventing a significant portion of the clot from progressing to the fully stabilized state (illustrated by the bottom panel of Figure 1).

	The Urea-Soluble Clot

Top Introduction The Urea-Soluble Clot The Urea-Insoluble Clot Activation and Regulation of... Determinants of the... What Lessons Can be... Therapeutic Possibilities References

 
The dramatic conversion of fibrinogen to fibrin is caused by the proteolytic action of thrombin with the release of N-terminal fibrinopeptide moieties^{5 6 7 8} (Figure 2a). These "caps" have to be removed from the protein for unmasking the self-assembly potential that was built into the parent fibrinogen molecule by evolution. The demonstration that thrombin was a protease provided the first example of a limited proteolytic type of control in the now familiar mode of regulation for most of the reactions of the coagulation and immunocomplement cascades. A key feature of the reaction of thrombin with fibrinogen is the generation of N-termini of glycine in fibrin^{9 10 11} because the immediate sequences of amino acids at these newly exposed sites¹² can serve as ligands for promoting the noncovalent assembly of fibrin molecules. Short peptide analogues of the natural sequences have been found to inhibit the clotting of purified fibrinogen.¹³

View larger version (27K): [in this window] [in a new window]   Figure 2. a) Generating the set of new N-termini of glycine in the limited proteolysis of fibrinogen by thrombin is the key for initiating the actual clotting reaction. The site of attack by thrombin in the critical step of releasing the fibrinopeptide A moiety from the A chain of the protein is shown. b) Release of fibrinopeptides (arrowheads) from fibrinogen triggers the process of self-assembly. The new N-terminal knobs, unmasked by thrombin in the central E domains bind to complementary holes in the D domains of the protein. Thus the E domain of 1 fibrin molecule makes non-covalent contacts with the D domains of 2 adjacent fibrins, aligning them end-to-end.

The fibrinopeptides (A and B) are located at the ends of the A and Bß chains of fibrinogen in the central E domain of the large molecule (Mw~340 000), made up of a disulfide bonded duplex of 3 different chains [ABß]₂.¹⁴ Release of fibrinopeptides by thrombin sets the train of events in motion for clotting by allowing the newly unmasked N-termini to interact with complementary holes (polymerization pockets) in the distal D domains of the protein.^{15 16 17} Actually, as seen from the activities of some snake venom enzymes, the release of fibrinopeptides A from the A chains alone is sufficient to initiate clotting.^{18 19} In either case, the E domain of one fibrin molecule makes contact with the D domains of 2 adjacent fibrins, neatly aligning them end-to-end (Figure 2b). This mode of assembly gives rise to the half-staggered arrangement of fibrin units in the protofibrils, recognized in the electronmicroscope with characteristic ca. 230Å repeats.^{20 21 22} Although prior thrombin cleavage is necessary for unmasking the N-terminal ligands, the polymerization pockets into which these knobs fit are fully accessible also in the fibrinogen molecule. Long filamentous assemblies can be obtained by mixing fibrinogen with fibrinopeptide-denuded E fragments derived from the plasmin digest of fibrin.²³

	The Urea-Insoluble Clot

Top Introduction The Urea-Soluble Clot The Urea-Insoluble Clot Activation and Regulation of... Determinants of the... What Lessons Can be... Therapeutic Possibilities References

 
There is a large family of Ca²⁺-dependent enzymes, widely distributed in nature and commonly referred to as transglutaminases, which promote the cross-linking of proteins by intermolecular N(-glutamyl)lysine side chain bridges. As first documented for the clotting of blood in crustaceans^{24 25} and also for the process of forming the copulation plug in rodents,²⁶ such transamidases may have served as the evolutionary prototypes of clotting enzymes. In the clotting of lobster blood, the enzyme is released from exploding amoebocytes, performing a platelet-like function. In the clotting of the seminal vesicle secretion proteins of rodents, the transglutaminase is secreted from another lobe of the prostate and becomes activated only in the vagina of the female as it encounters its substrates after ejaculation. In both phenomena, proteins are remodelled in a single enzymatic step, resulting in their transfer directly from a soluble phase into an insoluble coagulum, extensively cross-linked through covalent bonds. In sharp contrast, with vertebrate blood, cross-linking follows clotting and the factor XIIIa-catalyzed reaction is superimposed on a preformed assembly of an aligned and organized fibrin network. Thus, in the clotting of human blood, cross-linking contributes exclusively to the maturation and rigidification of the gel but does not significantly alter the morphology of the structure.

The covalent cross-linking of fibrin units occurs through an amide exchange reaction (transamidation) between select glutamine and lysine residues of neighboring protein molecules^{27 28 29 30 31} (Figure 3a). As a result, a few strategically located N(-glutamyl)lysine side chain bridges are formed. For the sake of simplicity, only 1 of the 2 bridges connecting the chains of 2 fibrins with an end-to-end orientation³² is shown in the figure. One should bear in mind, however, that factor XIIIa reacts with the , as well as the , chains of fibrin in an ordered sequence.³³ Crosslinks spanning more than 2 chains and several chains, giving rise to a variety of ₂, ₃, ₄ structures, homologous _n and hybrid _pq chain combinations, play important roles in clot stabilization.^{34 35 36 37 38} Furthermore, the factor XIIIa reaction is also responsible for the covalent attachment of a fraction of the ₂ plasmin inhibitor (₂PI, also referred to as ₂ antiplasmin or ₂AP) in plasma to the chains of some of the fibrin molecules, providing added protection against lytic agents.^{39 40}

View larger version (38K): [in this window] [in a new window]   Figure 3. a) Outline of the amide exchange stabilizing reaction catalyzed by factor XIIIa (A2*). Formation of N(-glutamyl)lysine bridges between the end-to-end aligned fibrin units are shown. b) Competitive inhibitors can block the factor XIIIa (A2*)-mediated crosslinking (ie, reaction 1) without interfering with the clotting time of the system. Serving as specific tracers, the inhibitors themselves become incorporated by the enzyme into the acceptor (reaction 2) and donor (reaction 3) cross-linking sites.

Human red cells contain a transglutaminase with a much broader substrate specificity than factor XIIIa. This enzyme can modify and crosslink fibrinogen as well as fibrin by and _n type of intra- and intermolecular N(-glutamyl)lysine bonds.³⁷ If the enzyme was released from trapped erythrocytes during the aging of the thrombi, its action would add to the complex pattern of cross-linking of the network.

Competitive,^{29 41 42 43} noncompetitive,⁴⁴ and active site-directed⁴⁵ inhibitors were shown to be able to selectively block clot stabilization by factor XIIIa without causing a delay in the clotting time of the system. The competitive compounds were useful for exploring the biochemical details of the cross-linking reaction because, by becoming incorporated into the donor and acceptor cross-linking residues, they served as specific labels for these sites (Figure 3b). Even more importantly, they made it possible to establish the fundamental paradigm for the present article, that selective interference with the functioning of the factor XIII system facilitates thrombolysis.^{46 47 48}

	Activation and Regulation of the Factor XIII System

Top Introduction The Urea-Soluble Clot The Urea-Insoluble Clot Activation and Regulation of... Determinants of the... What Lessons Can be... Therapeutic Possibilities References

 
As in the case with all other enzymes of the coagulation cascade, only the inactive precursor, ie, factor XIII, of the cross-linking enzyme circulates in plasma. The zymogen has an A₂B₂ subunit structure,⁴⁹ reminiscent of the heterologous tetrameric composition of hemoglobin. The A subunits possess the catalytic potential and, quite likely, the carrier B subunits serve the function of protecting them in the circulation. The B subunits also contribute to binding the zymogen to fibrinogen⁵⁰ and act as a brake on factor XIII activation.⁵¹ Thrombin and Ca²⁺ are required for conversion into the active factor XIIIa enzyme,^{52 53 54 55} but the thrombin-catalyzed cleavage near the N-termini of the A subunits only weakens the heterologous association of the subunits⁵⁶ and still leaves the zymogen in an inert tetrameric (A₂'B₂) form (Figure 4). Expression of enzyme activity depends on the Ca²⁺-facilitated dissociation of A₂' from the carrier B₂ subunits and on a concerted conformational change that unmasks the hidden sulfhydryl catalytic centers for the A₂* (FXIII_a) cross-linking enzyme.^{51 57} Although the other trypsin-like enzymes of the coagulation cascade operate with serine-OH active centers, factor XIIIa functions with a cysteine-SH catalytic residue, assisted by the imidazole ring of a histidine.^{58 59} There are remarkable kinetic^{60 61} and structural⁶² similarities with the papain-calpain family of enzymes, suggesting a common evolutionary ancestor.

View larger version (38K): [in this window] [in a new window]   Figure 4. Conversion of the factor XIII zymogen to the factor XIIIa (A2*) enzyme occurs in 2 distinct steps, promoted by thrombin and Ca2+, respectively. The thrombin-modified FXIII' intermediate is still inactive. Dissociation from the carrier B subunits facilitates the conformational change necessary for the unmasking of the active center cysteine thiol in the catalytic A* subunit.

Correct timing for the activation and operation of the factor XIII system is of critical significance for efficient hemostasis. This is reflected in the remarkably complex and tightly controlled series of interacting mechanisms that regulate the rate of conversion of the factor XIII zymogen, as well as the rate of cross-linking of fibrin by the activated enzyme. A key feature in synchronizing the clotting and cross-linking events is that thrombin plays the dual role of converting fibrinogen to fibrin and also initiates the process of activating the factor XIII zymogen. In addition, it has become evident that the fibrin substrate itself acts to coordinate the orderly sequence of reactions during the late stages of coagulation; as a feed-forward regulator, 1) it accelerates the cleavage of factor XIII by thrombin,⁶³ 2) it enables the subunits of the thrombin-modified zymogen to dissociate at the 1.5 mmol/L concentration of Ca²⁺ in plasma,⁶⁴ and 3) the noncovalent assembly of fibrin units speeds up the end-to-end fusion of the chains in the D domains of the protein.^{65 66} These unique controls (Figure 5) must have evolved to ensure that in the physiological sequence of events, only fibrin, and not the parent fibrinogen molecule, should be the target for cross-linking by factor XIIIa.

View larger version (36K): [in this window] [in a new window]   Figure 5. The reactions and controls that regulate clot stabilization were examined in purified systems, which then made possible the reconstruction of the entire physiological pathway.

	Determinants of the Morphological and Rheological Properties of the Clot Network

Top Introduction The Urea-Soluble Clot The Urea-Insoluble Clot Activation and Regulation of... Determinants of the... What Lessons Can be... Therapeutic Possibilities References

 
In the physiological milieu of pH, ionic strength, and Ca²⁺ concentration in plasma, clot morphology is determined mainly by the concentration of fibrinogen and by the thrombin activity generated at the site of injury. In addition, some proteins adhering to fibrin, eg, IgG and albumin, may add to fiber thickness.⁶⁷ With all other conditions being equal, scanning electronmicrographs show considerably tighter networks—characterized by greater fiber and branch point densities—near the upper end of the physiological range of fibrinogen concentration. Also, clots formed rapidly at higher concentrations of thrombin (with shorter clotting times) give rise to much tighter structures than their slowly forming counterparts generated at lower concentrations of thrombin (with longer clotting times).³⁸ Tightly knit clots would, of course, increase the likelihood of a higher degree of entrapment of blood cells in the network.

Remarkably, stabilization by the factor XIII system does not seem to affect clot morphology in regard to fiber and branch point densities, but the fibers become somewhat thinner and longer,^{38 68} suggesting that the covalent bonds introduced by factor XIIIa strengthen the internal architectures of the fibers themselves. Notwithstanding the morphological similarities, the properties of the network are greatly different because the clot can no longer be dissolved in 5 mol/L urea.^{2 3} Another sign of the profound change induced by the action of factor XIII is the large increase in the viscoelastic (storage) modulus, a measure of clot stiffness.^{69 70} To some extent, this quantity also correlates with the concentrations of fibrinogen and thrombin, but the role of factor XIII is paramount in this regard, causing an approximately 5-fold increase throughout the physiological range of fibrinogen concentration.³⁸

	What Lessons Can be Learned From Studying Disorders of Fibrin Stabilization?

Top Introduction The Urea-Soluble Clot The Urea-Insoluble Clot Activation and Regulation of... Determinants of the... What Lessons Can be... Therapeutic Possibilities References

 
Hemorrhaging may occur in some individuals in spite of the finding that the clotting and primary bleeding times are within the normal range of values. The hemostatic plug in these patients seems to fail because of extreme fragility and gives rise to a delayed oozing of blood at the wound site. Diagnosis usually rests on the observation that the recalcified plasma clot of the patient, unlike a normal one, can be solubilized in 5 mol/L urea.^{2 3} The hereditary lack of functional factor XIII zymogen is responsible for the majority of such cases,^{71 72 73} and most of them are due to the absence of the catalytic A subunits,^{74 75} although cases are also known with absence of B subunits.⁷⁶ Acquired inhibitors constitute yet another class with quite diverse etiologies in this family of disorders of fibrin stabilization.^{77 78} The natural inhibitors may interfere with 1 or more of the biochemical steps involved in the activation of the factor XIII zymogen (A₂B₂ A₂'B₂A₂*+B₂) or with the actual production of the covalent N(-glutamyl)lysine crosslinks catalyzed by the A₂*, factor XIIIa enzyme. Most of these inhibitors are found to be autoimmune antibodies directed against some of the molecules participating in the physiological sequence of events depicted in Figure 5.

In addition to the abnormal solubility in urea, the patients’ clots are much softer than normal showing very low viscoelastic moduli and a greatly enhanced susceptibility to digestion by lytic agents. These features can be illustrated with the experiments in Figure 6, carried out with factor XIII deficient plasmas. Panel A shows that supplementation with the purified A₂B₂ zymogen restored normal (approximately 5-fold) values to clot stiffness,⁷⁹ and the data in panel B demonstrate that supplementation with the zymogen (using only the recombinant A₂ subunits in this experiment) can also protect the clot against premature lysis (see also reference 80). These findings prove that proper functioning of the factor XIII system is required for imparting normal stiffness and adequate fibrinolytic resistance to the clot network.

View larger version (26K): [in this window] [in a new window]   Figure 6. Supplementation of factor XIII-deficient plasma with the missing factor can normalize values for clot stiffness (panel A) and increases resistance to lysis (right hand panel). Purified A2B2 plasma factor XIII (0.2 to 100x10-9 mol/L) was used in the experiments in panel A, whereas the recombinant A2 subunits of the zymogen were used (0 to 7 µg rA2) in panel B. The 0.2 mL mixtures for the latter comprised 0.1 mL of factor XIII-deficient citrated plasma, 0.6 U of thrombin, 12 mmol/L CaCl2, 25 mmol/L Tris-HCl buffer pH 7.5, and 20 IU TPA at 22°C (Lorand and Velasco, unpublished data, 1999).

	Therapeutic Possibilities

Top Introduction The Urea-Soluble Clot The Urea-Insoluble Clot Activation and Regulation of... Determinants of the... What Lessons Can be... Therapeutic Possibilities References

 
Detailed understanding of the molecular aspects of clot stabilization, together with the patient studies, provide the background for rational approaches aimed at exploring means for reducing the stiffness and lytic resistance of clots and thrombi. Results of some prototype experiments, employing cross-linking inhibitors such as discussed earlier (see Figure 3b) are presented in Figure 7. In a way, the findings are the mirror images of the data in panel A of Figure 6 because, as illustrated in Figure 7 (panel A), the inhibitors can actually reduce normal clot stiffness to approximately 20% of normal, corresponding to the value found in factor XIII-deficient plasma.⁷⁹ It is even more significant that the color photographs in panel B of Figure 7 provide decisive evidence that the specific inhibitors can also greatly enhance the susceptibilities of thrombi for digestion by lytic agents.^{47 48} These thrombi were formed from whole human blood in rotating plastic tubes (Chandler loop) in the absence and presence of a cross-linking inhibitor. They were indistinguishable before the addition of urokinase, but after 2 hours of exposure to the plasminogen activator, only a minuscule residue remained of the thrombus that was formed in the presence of the inhibitor, which was in stark contrast to the essentially undigested thrombus formed in the absence of the inhibitor.

View larger version (40K): [in this window] [in a new window]   Figure 7. Inhibitors of the factor XIIIa-catalyzed crosslinking reactions greatly reduce clot stiffness (panel A) and also the lytic resistance of thrombi (panel B). The ordinate of panel A indicates clot stiffness at 60 minutes (Gi,60') in the presence of crosslinking inhibitors, as percentages of the control value (Go,60') without inhibitors. The color photograph in panel B shows that, after 2 hours with 300 CTA units of urokinase (UK) at 37°C, the thrombus formed in the presence of 1 mmol/L tosylcadaverine, an inhibitor of crosslinking (XL), is completely lysed (d) whereas the control specimen (b) is still quite undigested. Photographs (a) and (c) are control thrombi without urokinase.

The validity of the notion that interference with any aspect of fibrin stabilization would produce similar effects is supported by numerous other experiments. Active center directed inhibitors of factor XIIIa were shown to be highly effective in reducing the viscoelastic moduli of clots³⁸ and also for the enhancement of clot lysis.⁴⁵ A protein isolated from the giant amazon leech was described to possess similar properties, although its mode of interaction with factor XIIIa is not yet known.^{81 82 83}

Positive results were obtained with a monoclonal antibody directed against the thrombin cleavage site of factor XIII, which blocked the activation of the zymogen.⁸⁴ Another interesting approach utilizes a monoclonal antibody against ₂PI.⁸⁵ As mentioned before, the factor XIIIa-catalyzed covalent attachment of ₂PI to fibrin significantly contributes to lytic resistance.^{40 41} In fact, the hemorrhagic manifestations in patients with ₂PI deficiency are being attributed to the excessive digestibility of the clot.⁸⁶ The antibody to ₂PI was shown to be effective in promoting clot lysis in vitro and thrombolysis in vivo in animal models.^{85 87 88 89} [Added in proof: Recent results from a mutant form of ₂PI point to more possibilities for enhancing the fibrinolytic susceptibilities of thrombi.⁹⁰ The Arg364Ala mutant, although no longer a plasmin inhibitor, competes effectively against the factor XIIIa-catalyzed incorporation of the wild type of ₂PI into fibrin. This approach is a special version of the competitive blocking of the donor cross-linking sites in fibrin, as depicted by reaction 3 in Figure 3b.]

The concept of utilizing inhibitors of clot stabilization as presented in this article provides a basic framework for developing new methodologies that, if translated to clinical practice, could facilitate thrombolysis with much lower doses of plasminogen activators than currently used. Significantly, as clotting time would not be lengthened, the extra risk of hemorrhage could be avoided.

	Acknowledgments

 
Support of the National Institutes of Health (HL-02212 and HL-16346) is gratefully acknowledged.

Received August 31, 1999; accepted November 2, 1999.

	References

Top Introduction The Urea-Soluble Clot The Urea-Insoluble Clot Activation and Regulation of... Determinants of the... What Lessons Can be... Therapeutic Possibilities References

 

1. Lorand L. Research on clot stabilization provides clues for improving thrombolytic therapies. Circulation. 1998;17(Supplement I):I-D. Abstract.
2. Lorand L. A study on the solubility of fibrin clots in urea. Hung Acta Physiol. 1948;1:192–196.
3. Laki K, Lorand L. On the solubility of fibrin clots. Science. 1948;108:280.[Free Full Text]
4. Meissner I, Wöhlisch E. Untersuchungen über die Einwirkung hydrotroper Substanzen auf das fibrinogen und die Blutgerinnung. Biochem Zietschrift. 1937;293:133–141.
5. Lorand L. "Fibrino-Peptide": aspects of the fibrinogen-fibrin transformation. Nature. 1951;167:992–994.[Medline] [Order article via Infotrieve]
6. Lorand L. Fibrino-peptide. Biochem J. 1952;52:200–203.[Medline] [Order article via Infotrieve]
7. Bettelheim FR, Bailey K. The products of the action of thrombin on fibrinogen. Biochim Biophys Acta. 1952;9:578–579.[Medline] [Order article via Infotrieve]
8. Doolittle RF, Blomback B. Amino acid sequence studies on fibrinopeptides from various mammals: evolutionary implications. Nature. 1964;202:147–152.[Medline] [Order article via Infotrieve]
9. Bailey K, Bettelheim FR, Lorand L, Middlebrook WR. Action of thrombin in the clotting of fibrinogen. Nature. 1951;167:233.[Medline] [Order article via Infotrieve]
10. Lorand L, Middlebrook WR. The action of thrombin on fibrinogen. Biochem J. 1952;52:196–199.[Medline] [Order article via Infotrieve]
11. Lorand L, Middlebrook WR. Species specificity of fibrinogen as revealed by end-group studies. Science. 1953;118:515–516.[Free Full Text]
12. Iwanaga S, Wallen P, Grondahl NJ, Henschen A, Blomback B. Isolation and characterization of N-terminal fragments obtained by plasmin digestion of human fibrinogen. Biochim Biophys Acta. 1967;147:606–609.[Medline] [Order article via Infotrieve]
13. Laudano AP, Doolittle RF. Studies on synthetic peptides that bind to fibrinogen and prevent fibrin polymerization. Structural requirements, numbers of binding sites and species differences. Biochemistry. 1980;19:1013–1019.[Medline] [Order article via Infotrieve]
14. Henschen A, Lottspeich F, Kehl M, Southan C. Covalent structure of fibrinogen. Ann N Y Acad Sci. 1983;408:28–43.[Medline] [Order article via Infotrieve]
15. Kudryk BJ, Collen D, Woods KR, Blomback B. Evidence for localization of polymerization sites in fibrinogen. J Biol Chem. 1974;249:3322–3325.[Abstract/Free Full Text]
16. Côté HCF, Pratt KP, Davie EW, Chung DW. The polymerization pocket "a" within the carboxyl-terminal region of the gamma chain of human fibrinogen is adjacent to but independent from the calcium-binding site. J Biol Chem. 1997;272:23792–23798.[Abstract/Free Full Text]
17. Spraggon G, Everse SJ, Doolittle RF. Crystal structures of fragment D from human fibrinogen and its crosslinked counterpart from fibrin. Nature. 1997;389:455–462.[Medline] [Order article via Infotrieve]
18. Nolan C, Hall LS, Barlow GH. Ancrod, the coagulating enzyme from the Malayan pit viper (Agkistrodon rhodostoma) venom. Methods Enzymol. 1976;45:205–213.[Medline] [Order article via Infotrieve]
19. Stocker K, Barlow GH. The coagulant enzyme from Bothrops atrox venom (Batroxobin). Methods Enzymol. 1976;45:214–223.[Medline] [Order article via Infotrieve]
20. Hall C, Slayter H. The fibrinogen molecule: its size, shape and mode of polymerization. J Biophys Biochem Cytology. 1959;5:11–15.
21. Cohen C. Weisel JW, Phillips GN Jr, Stauffacher CV, Fillers JP, Daub E. The structure of fibrinogen and fibrin: I. Electron microscopy and X-ray crystallography of fibrinogen. Ann N Y Acad Sci. 1983;408:194–213.[Medline] [Order article via Infotrieve]
22. Weisel JW, Phillips GN, Cohen C. The structure of fibrinogen and fibrin: II. Architecture of the fibrin clot. Ann N Y Acad Sci. 1983;408:367–379.[Abstract]
23. Veklich Y, Ang EK, Lorand L, Weisel JW. The complementary aggregation sites of fibrin investigated through examination of polymers of fibrinogen with fragment E. Proc Natl Acad Sci U S A. 1998;95:1438–1442.[Abstract/Free Full Text]
24. Lorand L, Doolittle RF, Konishi K, Riggs SK. A new class of blood coagulation inhibitors. Arch Biochem Biophys. 1963;102:171–179.[Medline] [Order article via Infotrieve]
25. Bruner-Lorand J, Urayama T, Lorand L. Transglutaminase as a blood clotting enzyme. Biochem Biophys Res Comm. 1966;23:828–834.[Medline] [Order article via Infotrieve]
26. Williams-Ashman HG, Notides AC, Pabalan SS, Lorand L. Transamidase reactions involved in the enzymic coagulation of semen: isolation of -glutamyl--lysine dipeptide from clotting secretion protein of guinea pig seminal vesicle. Proc Natl Acad Sci U S A. 1972;69:2322–2325.[Abstract/Free Full Text]
27. Lorand L, Ong HH. Studies on fibrin crosslinking. Nature of the acceptor groups in transpeptidation. Biochem Biophys Res Comm. 1966;23:188–193.[Medline] [Order article via Infotrieve]
28. Lorand L, Ong HH, Lipinski B, Rule NG, Downey J, Jacobsen A. Lysine as amine donor in fibrin crosslinking. Biochem Biophys Res Comm. 1966;25:629–637.
29. Lorand L, Rule NG, Ong HH, Furlanetto R, Jacobsen A, Downey J, Oner N, Bruner-Lorand J. Amine specificity in transpeptidation. Inhibition of fibrin crosslinking. Biochemistry. 1968;7:1214–1223.[Medline] [Order article via Infotrieve]
30. Matacic S, Loewy AG. The identification of isopeptide crosslinks in insoluble fibrin. Biochem Biophys Res Commun. 1968;30:356–362.[Medline] [Order article via Infotrieve]
31. Pisano JJ, Finlayson JS, Peyton MP. Crosslink in fibrin polymerized by factor XIII:(-glutamyl)lysine. Science. 1968;160:892–893.[Abstract/Free Full Text]
32. Chen R, Doolittle RF. Isolation, characterization and location of a donor-acceptor unit from crosslinking fibrin. Proc Natl Acad Sci U S A. 1970;66:472–479.[Abstract/Free Full Text]
33. Lorand L, Chenoweth D. Intramolecular localization of the acceptor crosslinking sites in fibrin. Proc Natl Acad Sci U S A. 1969;63:1247–1252.[Abstract/Free Full Text]
34. McKee PA, Mattock P, Hill RL. Subunit structure of human fibrinogen, soluble fibrin and crosslinked insoluble fibrin. Proc Natl Acad Sci U S A. 1970;66:738–744.[Abstract/Free Full Text]
35. Mosesson MW, Siebenlist KR, Amrani DL, DiOrio JP. Identification of covalently linked trimeric and tetrameric D domains in crosslinked fibrin. Proc Natl Acad Sci U S A. 1989;86:1113–1117.[Abstract/Free Full Text]
36. Mosesson MW, DiOrio JP, Siebenlist KR, Wall JS, Hainfeld JF. Evidence for a second type of fibril branch point in fibrin polymer networks, the trimolecular junction. Blood. 1993;82:1517–1521.[Abstract/Free Full Text]
37. Murthy SNP, Lorand L. Crosslinked A · chain hybrids serve as unique markers for fibrinogen polymerized by tissue transglutaminase. Proc Natl Acad Sci U S A. 1990;87:9679–9682.[Abstract/Free Full Text]
38. Ryan, EK, Mockros LF, Weisel JW, Lorand L. Structural origins of fibrin clot rheology. Biophys J. 1999;77:2813–2826.[Abstract/Free Full Text]
39. Sakata Y, Aoki N. Significance of crosslinking of ₂-plasmin inhibitor to fibrin in inhibition of fibrinolysis and in hemostasis. J Clin Invest. 1982;69:536–542.
40. Ichinose A, Tanaki T, Aoki N. Factor XIII-mediated crosslinking of NH2 terminal peptide of 2-plasmin inhibitor to fibrin. FEBS Lett. 1983;153:369–371.[Medline] [Order article via Infotrieve]
41. Nilsson JLG, Stenberg P, Ljunggren C, Hoffman KJ, Lunden R, Eriksson O, Lorand L. Fibrin-stabilizing factor inhibitors. Ann N Y Acad Sci. 1972;202:286–296.[Medline] [Order article via Infotrieve]
42. Parameswaran KN, Velasco PT, Wilson J, Lorand L. Labelling of -lysine crosslinking sites in proteins with peptide substrates of factor XIIIa and transglutaminase. Proc Natl Acad Sci U S A. 1990;87:8472–8475.[Abstract/Free Full Text]
43. Lorand L, Parameswaran KN, Velasco PT, Murthy SNP. Biotinylated peptides containing a factor XIIIa or tissue transglutaminase-reactive glutaminyl residue block protein crosslinking phenomena by becoming incorporated into amine donor sites. Bioconjugate Chem. 1992;3:37–41.[Medline] [Order article via Infotrieve]
44. Samama M, Soria J, Soria C, Maamer M, Otera AM. A new inhibitor of factor XIII and platelet aggregation INO 3178. In: Davidson JF, Cepelak V, Samama MM, Desnoyers PC (eds). Prog Chem Fibrinolysis Thrombolysis. New York: Churchill Livingstone; 1979;4:235–240.
45. Freund KF, Doshi KP, Gaul SL, Claremon DA, Remy DC, Baldwin JJ, Pitzenberger SM, Stern AM. Transglutaminase inhibition by 2-[(2-oxopropyl)thio]imidazolium derivatives: mechanism of factor XIIIa inactivation. Biochemistry. 1994;33:10109–10119.[Medline] [Order article via Infotrieve]
46. Lorand L, Jacobsen A. Accelerated lysis of blood clots. Nature. 1962;195:911–912.
47. Bruner-Lorand J, Pilkington TRE, Lorand L. Inhibitors of fibrin crosslinking: relevance for thrombolysis. Nature. 1966;210:1273–1274.[Medline] [Order article via Infotrieve]
48. Lorand L, Nilsson JLG. Molecular approach for designing inhibitors to enzymes involved in blood clotting. In Ariens EJ (ed). Drug Design. New York: Academic Press. 1972;3:415–417.
49. Schwartz, ML, Pizzo SV, Hill RL, McKee PA. Human factor XIII from plasma and platelets. Molecular weights, subunit structures, proteolytic activation, and crosslinking of fibrinogen and fibrin. J Biol Chem. 1973;248:1395–1407.[Abstract/Free Full Text]
50. Siebenlist KR, Meh DA, Mosesson MW. Plasma factor XIII binds specifically to fibrinogen molecules containing gamma chains. Biochemistry. 1996;35:10448–10453.[Medline] [Order article via Infotrieve]
51. Lorand L, Gray AJ, Brown K, Credo RB, Curtis CG, Domanik RA, Stenberg P. Dissociation of the subunit structure of fibrin stabilizing factor during activation of the zymogen. Biochem Biophys Res Commun. 1974;56:914–922.[Medline] [Order article via Infotrieve]
52. Lorand L, Konishi K. Activation of the fibrin stabilizing factor of plasma by thrombin. Arch Biochem Biophys. 1964;105:58–67.[Medline] [Order article via Infotrieve]
53. Mikuni Y, Iwanaga S, Konishi K. A peptide released from plasma fibrin stabilizing factor in the conversion to the active enzyme by thrombin. Biochem Biophys Res Commun. 1973;54:1393–1403.[Medline] [Order article via Infotrieve]
54. Nakamura S, Iwanaga S, Suzuki T, Mikuni Y, Konishi K. Amino acid sequence of the peptide released from bovine factor XIII following activation by thrombin. Biochem Biophys Res Commun. 1974;58:250–256.[Medline] [Order article via Infotrieve]
55. Takagi T, Doolittle RF. Amino acid sequence studies on factor XIII and the peptide released during its activation by thrombin. Biochemistry. 1974;13:750–756.[Medline] [Order article via Infotrieve]
56. Radek JT, Jeong J-M, Wilson J, Lorand L. Association of the A subunits of recombinant placental factor XIII with the native carrier B subunits from human plasma. Biochemistry. 1993;32:3527–3534.[Medline] [Order article via Infotrieve]
57. Curtis CG, Brown KL, Credo RB, Domanik RA, Gray A, Stenberg P, Lorand L. Calcium-dependent unmasking of active center cysteine during activation of fibrin stabilizing factor. Biochemistry. 1974;13:3774–3780.[Medline] [Order article via Infotrieve]
58. Parameswaran KN, Lorand L. New thioester substrates for fibrinoligase (Coagulation factor XIII_a) and for transglutaminase. Transfer of the fluorescently labeled acyl group to amines and alcohols. Biochemistry. 1981;20:3703–3711.[Medline] [Order article via Infotrieve]
59. Micanovic R, Procyk R, Lin W, Matsueda GR. Role of histidine 373 in the catalytic activity of coagulation factor XIII. J Biol Chem. 1994;269:9190–9194.[Abstract/Free Full Text]
60. Curtis CG, Stenberg P, Brown KL, Baron A, Chen K, Gray A, Simpson I, Lorand L. Kinetics of transamidating enzymes. Production of thiol in the reactions of thiol esters with fibrinoligase. Biochemistry. 1974;13:3257–3262.[Medline] [Order article via Infotrieve]
61. Stenberg P, Curtis CG, Wing D, Tong YS, Credo RB, Gray A, Lorand L. Transamidase kinetics. Amide formation in the enzymic reactions of thiol esters with amines. Biochem J. 1975;147:155–163.[Medline] [Order article via Infotrieve]
62. Pedersen LC, Yee VC, Bishop PD, Teller DC, Stenkamp RE. Transglutaminase factor XIII uses proteinase-like catalytic triad to crosslink macromolecules. Protein Sci. 1994;3:1131–1135.[Abstract]
63. Naski MG, Lorand L, Shafer J. Characterization of the kinetic pathway for fibrin promoting of -thrombin-catalyzed activation of plasma factor XIII. Biochemistry. 1991;30:934–941.[Medline] [Order article via Infotrieve]
64. Credo RB, Curtis CG, Lorand L. -Chain domain of fibrinogen controls generation of fibrinoligase (Coagulation factor XIII_a). Calcium ion regulatory aspects. Biochemistry. 1981;20:3770–3778.[Medline] [Order article via Infotrieve]
65. Samokhin GP, Lorand L. Contact with the N-termini in the central E domain enhances the reactivities of the distal D domains of fibrin to factor XIII_a. J Biol Chem. 1995;270:21827–21832.[Abstract/Free Full Text]
66. Lorand L, Parameswaran KN, Murthy SNP. A double-headed GlyProArgPro ligand mimics the functions of the E domain of fibrin for promoting the end-to-end crosslinking of chains by factor XIII_a. Proc Natl Acad Sci U S A. 1998;95:537–541.[Abstract/Free Full Text]
67. Carr MF. Fibrin formed in plasma is composed of fibers more massive than those formed from purified fibrinogen. Thromb Haemostasis. 1988;59:535–539.[Medline] [Order article via Infotrieve]
68. Glover CJ, McIntire LV, Brown CH, Natelson EA. Rheological properties of fibrin clots. Effects of fibrinogen concentration, factor XIII deficiency, and factor XIII inhibition. J Lab Clin Med. 1975;86:644–656.[Medline] [Order article via Infotrieve]
69. Roberts WW, Lorand L, Mockros LF. Viscoelastic properties of fibrin clots. Biorheology. 1973;10:29–42.[Medline] [Order article via Infotrieve]
70. Mockros LF, Roberts WW, Lorand L. Viscoelastic properties of ligation-inhibited fibrin clots. Biophys Chem. 1974;2:164–169.[Medline] [Order article via Infotrieve]
71. Lorand L, Urayama T, DeKiewiet JWC, Nossel HL. Diagnostic and genetic studies on fibrin-stabilizing factor with a new assay based on amine incorporation. J Clin Invest. 1969;48:1054–1064.
72. Lorand L, Urayama T, Atencio AC, Hsia DY-Y. Inheritance of deficiency of fibrin-stabilizing factor (factor XIII). Am J Hum Genet. 1970;22:89–95.[Medline] [Order article via Infotrieve]
73. Lorand L, Losowsky MS, Miloszewski KJM. Human factor XIII: Fibrin stabilizing factor. In: Spaet TH (ed). Progress in Hemostasis and Thrombosis. New York:Grune & Stratton; 1980;5:245–290.
74. Ichinose A, Kaetsu H. Molecular approach to structure-function relationship of human coagulation factor XIII. Methods Enzymol. 1993;222:36–51.[Medline] [Order article via Infotrieve]
75. Mikkola H, Yee VC, Syrjälä M, Seitz R, Egbring R, Petrini P, Ljung R, Ingerslev J, Teller DC, Peltonen L, Palotie A. Four novel mutations in deficiency of coagulation factor XIII: consequences to expression and structure of the A-subunit. Blood. 1996;87:141–151.[Abstract/Free Full Text]
76. Izume T, Hashiguchi T, Castaman G, Tosetto A, Rodeghiero F, Girolami A, Ichinose A. Type 1 factor XIII deficiency is caused by a genetic defect of its b subunit: insertion of triplet AAC in exon III leads to premature termination in the second Sushi domain. Blood. 1996;87:2769–2774.[Abstract/Free Full Text]
77. Lorand L. Acquired inhibitors of fibrin stabilization: a class of hemorrhagic disorders of diverse origins. In: Green D (ed). Anticoagulants, Physiologic, Pathologic and Pharmacologic. Cleveland: CRC Press; 1994;169–191.
78. Lorand L, Velasco PT, Murthy SNP, Lefebvre P, Green D. Autoimmune antibody in a hemorrhagic patient interacts with thrombin-activated factor XIII in a unique manner. Blood. 1999;93:909–917.[Abstract/Free Full Text]
79. Shen L, Lorand L. Contribution of fibrin stabilization to clot strength. Supplementation of factor XIII-deficient plasma with the purified zymogen. J Clin Invest. 1983;71:1336–1341.
80. Edwards MW, deBang E, Strout J, Bishop PD. Recombinant factor XIII supplemented clots resist lysis by plasmin and leucocyte elastase. Fibrinolysis. 1993;7:211–216.
81. Seale L, Finney S, Sawyer RT, Wallis RB. Tridegin, a novel peptidic inhibitor of factor XIIIa from the leech, Haementeria ghilianii, enhances fibrinolysis in vitro. Thromb Haemost. 1997;77:959–963.[Medline] [Order article via Infotrieve]
82. Wallis RB, Seale L, Finney S, Sawyer RT, Bennett GM, Ross-Murphy SB. Reduction of plasma clot stability by a novel factor XIIIa inhibitor from the giant Amazon leech, Haementeria ghilianii. Blood Coagul Fibrinolysis. 1997;8:291–295.[Medline] [Order article via Infotrieve]
83. Finney S, Seale L, Sawyer RT, Wallis RB. Tridegin a new peptidic inhibitor of factor XIIIa, from the blood-sucking leech Haementeria ghilianii. Biochem J. 1997;324:797–805.
84. Reed GL III, Lukacova D. Generation and mechanism of action of a potent inhibitor of factor XIII function. Thromb Haemostasis. 1995;74:680–685.[Medline] [Order article via Infotrieve]
85. Reed GL III, Matsueda GR, Haber E. Synergistic fibrinolysis: Combined effects of plasminogen activators and an antibody that inhibits ₂ antiplasmin. Proc Natl Acad Sci U S A. 1990;87:1114–1118.[Abstract/Free Full Text]
86. Aoki N, Saito T, Kamiya T, Koie K, Sakata Y, Kobakura M. Congenital deficiency of ₂-plasmin inhibitor associated with severe hemorrhagic tendency. J Clin Invest. 1979;63:877–884.
87. Reed GL III, Matsueda GR, Haber E. Inhibition of clot bound ₂-antiplasmin enhances in vivo thrombolysis. Circulation. 1990;82:164–168.[Abstract/Free Full Text]
88. Butte AN, Houng AK, Jang I-Kyung, Reed GL. ₂-Antiplasmin causes thrombi to resist fibrinolysis induced by tissue plasminogen activator in experimental pulmonary embolism. Circulation. 1997;95:1886–1891.[Abstract/Free Full Text]
89. Reed GL, Houng AK. The contribution of activated factor XIII to fibrinolytic resistance in experimental pulmonary embolism. Circulation. 1999;99:299–304.[Abstract/Free Full Text]
90. Lee KN, Tae WC, Jackson KW, Kwon SH, McKee PA. Characterization of wild-type and mutant ₂-antiplasmins: fibrinolysis enhancement by reactive site mutant. Blood. 1999;94:164–171.[Abstract/Free Full Text]

This article has been cited by other articles:

				L. Lorand Crosslinks in blood: transglutaminase and beyond FASEB J, June 1, 2007; 21(8): 1627 - 1632. [Full Text] [PDF]

				L. O. Mosnier and B. N. Bouma Regulation of Fibrinolysis by Thrombin Activatable Fibrinolysis Inhibitor, an Unstable Carboxypeptidase B That Unites the Pathways of Coagulation and Fibrinolysis Arterioscler. Thromb. Vasc. Biol., November 1, 2006; 26(11): 2445 - 2453. [Abstract] [Full Text] [PDF]

				R. Park, H.-J. Doh, S.-S. A. An, J.-R. Choi, K.-H. Chung, and K.-S. Song A novel fibrinogen variant (fibrinogen Seoul II; A{alpha}Gln328Pro) characterized by impaired fibrin {alpha}-chain cross-linking Blood, September 15, 2006; 108(6): 1919 - 1924. [Abstract] [Full Text] [PDF]

				J.-P. Collet, J. L. Moen, Y. I. Veklich, O. V. Gorkun, S. T. Lord, G. Montalescot, and J. W. Weisel The {alpha}C domains of fibrinogen affect the structure of the fibrin clot, its physical properties, and its susceptibility to fibrinolysis Blood, December 1, 2005; 106(12): 3824 - 3830. [Abstract] [Full Text] [PDF]

				J.-P. Collet, H. Shuman, R. E. Ledger, S. Lee, and J. W. Weisel The elasticity of an individual fibrin fiber in a clot PNAS, June 28, 2005; 102(26): 9133 - 9137. [Abstract] [Full Text] [PDF]

				L. LORAND Factor XIII: Structure, Activation, and Interactions with Fibrinogen and Fibrin Ann. N.Y. Acad. Sci., June 1, 2001; 936(1): 291 - 311. [Abstract] [Full Text] [PDF]

This Article Full Text (PDF)